Literature DB >> 24938636

Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.

Kristen M Williams1, Danielle Dietzen, Abeer A Hassoun, Ilene Fennoy, Monica Bhatia.   

Abstract

Allogenic hematopoietic cell transplantation (alloHCT) is currently the only curative treatment option for patients with sickle cell disease. Alemtuzumab is a monoclonal antibody directed against CD52 positive cells used in myeloablative conditioning regimens for alloHCT. Its use has been associated with development of autoimmune disease in adult patients with rheumatologic conditions. We report on three cases of new onset autoimmune thyroid disease after alloHCT treatment with alemtuzumab in pediatric patients with sickle cell disease.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  alemtuzumab; autoimmunity; sickle cell disease; stem cell transplant; thyroid dysfunction

Mesh：

Substances：

Year:  2014        PMID： 24938636      PMCID： PMC4440678          DOI： 10.1002/pbc.25102

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  20 in total

1.  Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002.

Authors:  Emad Yanni; Scott D Grosse; QuanHe Yang; Richard S Olney
Journal:  J Pediatr       Date:  2008-11-22       Impact factor: 4.406

2.  Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.

Authors:  S Slavin; R Or; L Weiss; D Steiner-Zalz; G Cividalli; C Brautbar; Z Weshler; E Galun; S Samuels; D Galili
Journal:  Adv Exp Med Biol       Date:  1985       Impact factor: 2.622

3.  Endocrine complications following pediatric bone marrow transplantation.

Authors:  Josephine Ho; Victor Lewis; Gregory M T Guilcher; David K Stephure; Danièle Pacaud
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

4.  Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells.

Authors:  G M Davison; N Novitzky; A Kline; V Thomas; L Abrahams; G Hale; H Waldmann
Journal:  Transplantation       Date:  2000-04-15       Impact factor: 4.939

Review 5.  Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review.

Authors:  A Ashley-Koch; Q Yang; R S Olney
Journal:  Am J Epidemiol       Date:  2000-05-01       Impact factor: 4.897

6.  Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence.

Authors:  Hiroyuki Ishiguro; Yukiharu Yasuda; Yuuichiro Tomita; Tsuyoshi Shinagawa; Takashi Shimizu; Tsuyoshi Morimoto; Kinya Hattori; Masae Matsumoto; Hiroyasu Inoue; Hiromasa Yabe; Miharu Yabe; Osamu Shinohara; Shunichi Kato
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

Review 7.  Immune reconstitution syndrome and the thyroid.

Authors:  Anthony Weetman
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

8.  Thyroid function following hematopoietic cell transplantation in children: 30 years' experience.

Authors:  Jean E Sanders; Paul A Hoffmeister; Ann E Woolfrey; Paul A Carpenter; Barry E Storer; Rainer F Storb; Frederick R Appelbaum
Journal:  Blood       Date:  2008-10-06       Impact factor: 22.113

9.  Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood.

Authors:  B Bakker; W Oostdijk; D Bresters; M J E Walenkamp; J M Vossen; J M Wit
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

10.  Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.

Authors:  Françoise Bernaudin; Gérard Socie; Mathieu Kuentz; Sylvie Chevret; Michel Duval; Yves Bertrand; Jean-Pierre Vannier; Karima Yakouben; Isabelle Thuret; Pierre Bordigoni; Alain Fischer; Patrick Lutz; Jean-Louis Stephan; Nathalie Dhedin; Emmanuel Plouvier; Geneviève Margueritte; Dominique Bories; Suzanne Verlhac; Hélène Esperou; Lena Coic; Jean-Paul Vernant; Eliane Gluckman
Journal:  Blood       Date:  2007-07-02       Impact factor: 22.113
View more
  3 in total

Review 1.  Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.

Authors:  Mario Rotondi; Martina Molteni; Paola Leporati; Valentina Capelli; Michele Marinò; Luca Chiovato
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-28       Impact factor: 5.555

2.  Adrenal crisis in a 14-year-old boy 12 years after hematopoietic stem cell transplantation.

Authors:  Theresa Penger; Andrea Albrecht; Michaela Marx; Daniel Stachel; Markus Metzler; Helmuth G Dörr
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-06-06

3.  Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?

Authors:  Luminita Nicoleta Cima; Ioana Maria Lambrescu; Lavinia Stejereanu; Anca Colita; Reuven Or; Simona Fica
Journal:  Clin Case Rep       Date:  2018-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.